Journal of Hematology and Oncology Research

Aims and Scope

 

Open Access Pub launches the Open Peer Reviewed Journal -” Journal of Hematology and Oncology Research ISSN NO: 2372-6601”. The journal aims to cover the latest outstanding developments in Hematology and Oncology. 

 

The Journal of Hematology and Oncology Research is a scientific journal that aims to advance the understanding of hematological and oncological conditions and their treatments. We publish high-quality research that covers a wide range of topics, including blood disorders, cancer care i.e. diagnosis and treatment, and immunology, Gynecologic Oncology, Radiation Oncology, Oral Oncology, Molecular Oncology, Cellular Oncology, Pediatric Hematology and Pediatric Oncology, Surgical Oncology, Neuro Oncology.

 

Current Oncology is a multidisciplinary medium for clinical oncologists to report and review progress in the management of cancer. Our journal is dedicated to promoting the exchange of ideas and information among researchers, clinicians, and other professionals working in the field of hematology and oncology. To achieve this goal, we publish original research articles, review articles, case reports, and letters to the editor.

 

The scope of our journal includes, but is not limited to, the following topics:

 

Blood disorders: We welcome submissions on a wide range of blood disorders, including anemia, bleeding disorders, blood clots, blood cancers (such as leukemia and lymphoma), and disorders of white blood cells and platelets.

 

Cancer diagnosis and treatment: We are interested in articles that cover various aspects of cancer diagnosis, treatment, and management, including novel diagnostic techniques, surgical interventions, chemotherapy, radiation therapy, and targeted therapies.

 

Immunology: Our journal also publishes research on the immune system and its role in hematological and oncological conditions. This includes studies on immune-mediated diseases, immune dysfunction, and the development of immune-based therapies.

• Hematological conditions, such as blood cancers (leukemia, lymphoma, and multiple myeloma)Oncological conditions, including solid tumors and hematological malignancies.
• Diagnostic and therapeutic approaches for hematological and oncological conditions, including chemotherapy, immunotherapy, and targeted therapies.
• Basic and translational research on the pathogenesis of hematological and oncological conditions.
• Clinical trials and observational studies on the effectiveness and safety of treatments for hematological and oncological conditionsHealth services research and policy issues related to hematology and oncology.
• Psychosocial and quality of life issues in patients with hematological and oncological conditions and their caregivers.

 

We encourage submissions from researchers and clinicians around the world and welcome a diversity of viewpoints and approaches. In order to be considered for publication, all submissions must meet the highest standards of scientific rigor and clinical relevance.

 

JHOR committed to promoting the exchange of ideas and information among researchers, clinicians, and other professionals working in the field. By publishing high-quality research, we aim to contribute to the advancement of knowledge and the improvement of patient care in the field of hematology and oncology.

 

We believe that the research published in our journal has the potential to make a significant impact on the lives of patients and their families. By advancing the understanding of hematological and oncological conditions and their treatments, we hope to contribute to the development of better diagnostic and therapeutic approaches and ultimately improve patient outcomes.

 

Contributions from the following research areas are invited but not limited to the following branches :

• ​Anemia
• Leukemia
• Skin cancer
• Cancer
• Breast cancer
• Palliative care
• Cervical cancer
• Oncology
• Lung cancer
• Ovarian cancer
• Epigenetics
• Chemotherapy
• Hematology
• Leukocytes
• Platelets
• Endometrial cancer
• Genetics
• Immunotherapy
• Uterine cancer
• Vulvar cancer
• Head and neck cancer
• Acute myeloid leukemia
• Blood-transfusion
• Hematopoiesis
• B-Cell-lymphoma
• Vaginal cancer
• Radiation oncology
• Haemophilia
• Sarcomas
• Gynecologic oncology
• Signal transduction
• Cytogenetics
• Oncologists
• Pediatric oncology
• Medical oncology
• Surgical oncology
• Tumor markers
• Bleeding disorders
• Pharmacogenetics
• Hemolytic anemias
• Leukaemia
• Clinical cancer research
• Fallopian tube cancer
• Hematologic malignancies
• Hematopoietic stem cell transplantation
• Anemias
• Gastrointestinal cancer
• Germ cell tumors
• Oncological
• Tumor microenvironment
• Cancer vaccines
• Platelet disorders
• Urologic oncology
• Aplastic anaemia
• Cell and molecular biology
• Genitourinary cancer
• Leukemias
• Neuro-oncology
• Thoracic cancer
• Clinical medicine
• Hematological malignancies
• Preleukemia
• Solid tumors
• Cancer immunology 
• Interventional oncology
• Ocular oncology
• Cancer genomics
• Cancer imaging
• Haematological malignancies
• Paediatric oncology
• Molecular oncology
• Drug design
• Leukemogenesis
• Clinical oncology
• Hematopoietic cell
• Neurooncology
• Chemoresistance
• Global oncology
• Hemorrhagic disorders
• Neurosurgical oncology
• Oncologic surgery ·
• Blood coagulation disorders
• Blood platelet disorders
• Cancer pharmacology
• Blood group incompatibility
• General hematology
• Cancer stem cell biology
• Tumor surveillance
• Allergo oncology
• Blood protein disorders
• Common blood cancers
• Gynecologic cancer prevention
• Gynecologic cancer screening
• Steroid cell tumor
• Blood and marrow transplantation
• Cancer in pregnancy
• Drug design and development
• Hematology-oncology
• Hematologic neoplasia
• Gene Transfer for Anemia
• Genetics of immune function
• Sickle cell disorders
• Platelets in thrombosis 
• Ovarian sex cord-stromal tumors
• Red and white blood cell disorders
• Sex cord stromal tumors
• Tumor sensitization
• Aids and gynecologic cancers
• All solid and hematological cancers
• Chemotherapy and viral oncology.
• Clinical neuro-oncology
• Epithelial ovarian cancer and primary peritoneal cancer
• Genetics and hereditary cancer
• Hematologic pregnancy complications
• Leukocytes and hematopoiesis
• Malignant ovarian germ cell tumors
• Mixed müllerian tumor
• Molecular diagnostics and targeted cancer therapies
• Nonsurgical tumor ablation
• Recent developments in tumor therapy · 
• Science of blood transfusion
• Stem cells and hematopoiesis